Home > Insider Trading > Filing (0000899243-22-021934)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1832415	Better Therapeutics Inc.	BTTX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1807550	J. Andrew Armanino	C/O Better Therapeutics, Inc. 548 Market Street, #49404 San Francisco CA 94104		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-06-09	25,000	$1.65	151,328	No	4	P	Indirect	By Armanino Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Armanino Trust

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2022-06-09	15,000	$0.00	15,000	$1.66

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
15,000		2032-06-08	No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	13,334	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.6475 to $1.6791, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
These shares are owned directly by the Andrew J. Armanino III and Denise M. Armanino Family Trust (the "Armanino Trust"), and indirectly by the Reporting Person and his spouse, Denise M. Armanino, as trustees of the Armanino Trust.
The stock option vests in full on the earlier of the first anniversary of the grant date and the Issuer's next annual meeting of stockholders, provided that the Reporting Person continues to serve as a director of the Issuer on such vesting date. The stock option was granted on June 9, 2022.